An investigation on behalf of investors in TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) shares over potential wrongdoing at TRACON Pharmaceuticals, Inc. was announced.
San Diego, CA -- (SBWIRE) -- 05/04/2021 -- An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at TRACON Pharmaceuticals, Inc.
Investors who purchased shares of TRACON Pharmaceuticals, Inc. (NASDAQ: TCON) have certain options and should contact the Shareholders Foundation at email@example.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain TRACON Pharmaceuticals directors breached their fiduciary duties and caused damage to the company and its shareholders.
San Diego, CA based TRACON Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer and age-related macular degeneration and fibrotic diseases in the United States. Shares of TRACON Pharmaceuticals, Inc. (NASDAQ: TCON) declined from $11.76 per share on February 16, 2021, to as low as $7.08 per share on April 20, 2021,
Those who purchased shares of TRACON Pharmaceuticals, Inc. (NASDAQ: TCON), have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.